Immunotherapy in cervix cancer

Laura Attademo, Valentina Tuninetti, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Rosa Tambaro, Giorgio Valabrega, Lucia Musacchio, Sergio Venanzio Setola, Patrizia Piccirillo, Daniela Califano, Anna Spina, Simona Losito, Stefano Greggi, Sandro Pignata

Research output: Contribution to journalReview articlepeer-review


The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to improve outcomes, as the prognosis is still poor. In the last years, a better understanding of HPV tumor–host immune system interactions and the development of new therapeutics targeting immune checkpoints generated interest in the use of immunotherapy in cervix cancer. Preliminary phase I–II trials demonstrated the efficacy, the duration of responses and the manageable safety of this approach. Currently, many phase II and III studies are ongoing in both locally advanced and metastatic cervical cancer, assessing immunotherapy as a single agent or in combination with chemotherapy and radiotherapy. We reviewed the published data and the therapeutic implications of the most promising novel immunotherapeutic agents under investigation in cervix cancer.

Original languageEnglish
Article number102088
JournalCancer Treatment Reviews
Publication statusPublished - Nov 2020


  • Cervix cancer
  • HPV
  • Immune checkpoint inhibitor
  • Immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Immunotherapy in cervix cancer'. Together they form a unique fingerprint.

Cite this